ResMed (RMD) Q4 2026 Earnings Call Transcript
ResMed’s Q4 2026 earnings call transcript outlines fiscal 2026 execution and fiscal 2027 priorities: operational and innovation excellence, portfolio management, and using free cash flow to reinvest and return capital. Management cited early Oura partnership results (about 13,000 users to ResMed.com) and claims-data analysis on GLP-1s and PAP therapy adherence, plus AirSense 11 global rollout and new AirCurve 11 launches.
How this was made
The 30-second read
Why it matters
The excerpt provides quantified early partnership traction (Oura), updated claims-based GLP-1 read-through statistics, and specific device rollout milestones (AirSense 11 and AirCurve 11 platforms), which can shift investor expectations for connected-care growth and demand generation. It also reiterates commitment and execution focus around a field safety corrective action, which remains a key risk factor.
Market read
Traders can use the quantified Oura engagement and reiterated GLP-1 and device rollout momentum to reassess near-term demand and connected-care adoption, while monitoring corrective-action execution risk.
What to watch
Ongoing Astral field safety corrective action could create supply, service, or cost pressures that offset growth from new partnerships and device rollouts.
Background
This is a transcript-style excerpt from ResMed’s Q4 2026 earnings call, focusing on FY2027 priorities, sleep-health pathway strategy, and product and partnership updates.
Ticker impact
ResMed’s Q4 2026 call outlines FY2027 priorities, including AirSense 11 rollout progress and early Oura partnership performance driving sleep assessments.
Near-term sentiment likely supported by quantified partnership engagement and continued device/software rollout, partially offset by ongoing corrective-action overhang.
The transcript provides specific operational metrics (13,000 users to ResMed.com from Oura app, ~75% previously undiagnosed) and concrete product milestones (AirSense 11 global rollout, AirCurve 11 ST/ST-A introductions), but it does not include fresh financial guidance numbers in the provided excerpt.
Market effects
Reinforces the sleep-apnea device and digital-health ecosystem thesis, linking wearables and GLP-1 adoption to CPAP initiation and adherence.
Highlights faster AirSense 11 penetration after China launch and device introductions across Europe and Asia-Pacific, which can influence regional channel expectations.
Positions ResMed as scaling a common connected-care platform across underpenetrated core markets, potentially affecting competitive dynamics in home sleep diagnostics and therapy.
Counterpoint
Early Oura partnership engagement may not translate into durable therapy starts or revenue without evidence of conversion rates beyond assessments.
Key entities
- companyResMed
Sleep and breathing health company discussing FY2027 priorities, Oura partnership traction, GLP-1 read-through, and AirSense/AirCurve device rollouts.
- companyOura
Wearable ring-based technology partner referenced for early performance driving users to ResMed.com and sleep assessments.
- companySamsung
Mentioned as pursuing FDA clearance for Galaxy Ring sleep apnea detection capability.
